|
1
|
Aaron AD: The management of cancer
metastatic to bone. JAMA. 272:1206–1209. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Dominguez DE, Lauper N, Velastegui A and
Reynolds J: Surgical management of the spinal metastases. Rev Med
Suisse. 12:2168–2171. 2016.In French.
|
|
3
|
Wu AS and Fourney DR: Evolution of
treatment for metastatic spine disease. Neurosurg Clin N Am.
15:401–411. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Dushyanthen S, Cossigny DA and Quan GM:
The osteoblastic and osteoclastic interactions in spinal metastases
secondary to prostate cancer. Cancer Growth Metastasis. 6:61–80.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Choi D, Crockard A, Bunger C, Harms J,
Kawahara N, Mazel C, Melcher R and Tomita K; Global Spine Tumor
Study Group: Review of metastatic spine tumour classification and
indications for surgery: the consensus statement of the Global
Spine Tumour Study Group. Eur Spine J. 19:215–222. 2010. View Article : Google Scholar :
|
|
6
|
Muralidharan A and Smith MT: Pathobiology
and management of prostate cancer-induced bone pain: Recent
insights and future treatments. Inflammopharmacology. 21:339–363.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Jemal A, Siegel R, Ward E, Murray T, Xu J
and Thun MJ: Cancer statistics, 2007. CA Cancer J Clin. 57:43–66.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Przybyla BD, Shafirstein G, Vishal SJ,
Dennis RA and Griffin RJ: Molecular changes in bone marrow, tumor
and serum after conductive ablation of murine 4T1 breast carcinoma.
Int J Oncol. 44:600–608. 2014. View Article : Google Scholar :
|
|
9
|
Salazar N, Castellan M, Shirodkar SS and
Lokeshwar BL: Chemokines and chemokine receptors as promoters of
prostate cancer growth and progression. Crit Rev Eukaryot Gene
Expr. 23:77–91. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Liao YX, Zhou CH, Zeng H, Zuo DQ, Wang ZY,
Yin F, Hua YQ and Cai ZD: The role of the CXCL12-CXCR4/CXCR7 axis
in the progression and metastasis of bone sarcomas (Review). Int J
Mol Med. 32:1239–1246. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Liu JF, Tsao YT and Hou CH:
Fractalkine/CX3CL1 induced intercellular adhesion
molecule-1-dependent tumor metastasis through the
CX3CR1/PI3K/Akt/NF-κB pathway in human osteosarcoma. Oncotarget.
8:54136–54148. 2016.
|
|
12
|
Tardáguila M, Mira E, García-Cabezas MA,
Feijoo AM, Quintela-Fandino M, Azcoitia I, Lira SA and Mañes S:
CX3CL1 promotes breast cancer via transactivation of the EGF
pathway. Cancer Res. 73:4461–4473. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Tang J, Xiao L, Cui R, Li D, Zheng X, Zhu
L, Sun H, Pan Y, Du Y and Yu X: CX3CL1 increases invasiveness and
metastasis by promoting epithelial-to-mesenchymal transition
through the TACE/TGF-α/EGFR pathway in hypoxic androgen-independent
prostate cancer cells. Oncol Rep. 35:1153–1162. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ferretti E, Pistoia V and Corcione A: Role
of fractalkine/CX3CL1 and its receptor in the pathogenesis of
inflammatory and malignant diseases with emphasis on B cell
malignancies. Mediators Inflamm. 2014:4809412014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Shulby SA, Dolloff NG, Stearns ME, Meucci
O and Fatatis A: CX3CR1-fractalkine expression regulates cellular
mechanisms involved in adhesion, migration, and survival of human
prostate cancer cells. Cancer Res. 64:4693–4698. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Jamieson WL, Shimizu S, D'Ambrosio JA,
Meucci O and Fatatis A: CX3CR1 is expressed by prostate epithelial
cells and androgens regulate the levels of CX3CL1/fractalkine in
the bone marrow: Potential role in prostate cancer bone tropism.
Cancer Res. 68:1715–1722. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Liu W, Bian C, Liang Y, Jiang L, Qian C
and Dong J: CX3CL1: A potential chemokine widely involved in the
process spinal metastases. Oncotarget. 8:15213–15219.
2017.PubMed/NCBI
|
|
18
|
Wiemer AJ, Wernimont SA, Cung TD, Bennin
DA, Beggs HE and Huttenlocher A: The focal adhesion kinase
inhibitor PF-562,271 impairs primary CD4+ T cell
activation. Biochem Pharmacol. 86:770–781. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yu W, He X, Ni Y, Ngeow J and Eng C:
Cowden syndrome-associated germline SDHD variants alter PTEN
nuclear translocation through SRC-induced PTEN oxidation. Hum Mol
Genet. 24:142–153. 2015. View Article : Google Scholar
|
|
20
|
Lee BY, Hochgräfe F, Lin HM, Castillo L,
Wu J, Raftery MJ, Martin Shreeve S, Horvath LG and Daly RJ:
Phosphoproteomic profiling identifies focal adhesion kinase as a
mediator of docetaxel resistance in castrate-resistant prostate
cancer. Mol Cancer Ther. 13:190–201. 2014. View Article : Google Scholar
|
|
21
|
Rabbani SA, Valentino ML, Arakelian A, Ali
S and Boschelli F: SKI-606 (Bosutinib) blocks prostate cancer
invasion, growth, and metastasis in vitro and in vivo through
regulation of genes involved in cancer growth and skeletal
metastasis. Mol Cancer Ther. 9:1147–1157. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-DeltaDeltaC(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
23
|
Li HY, Cui XY, Wu W, Yu FY, Yao HR, Liu Q,
Song EW and Chen JQ: Pyk2 and Src mediate signaling to
CCL18-induced breast cancer metastasis. J Cell Biochem.
115:596–603. 2014. View Article : Google Scholar
|
|
24
|
Sarabia-Estrada R, Zadnik PL, Molina CA,
Jimenez-Estrada I, Groves ML, Gokaslan ZL, Bydon A, Witham TF,
Wolinsky JP and Sciubba DM: A rat model of metastatic spinal cord
compression using human prostate adenocarcinoma: Histopathological
and functional analysis. Spine J. 13:1597–1606. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Sun Y, Wang F, Sun X, Wang X, Zhang L and
Li Y: CX3CR1 regulates osteoarthrosis chondrocyte proliferation and
apoptosis via Wnt/beta-catenin signaling. Biomed Pharmacother.
96:1317–1323. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wang H, Cai J, Du S, Guo Z, Xin B, Wang J,
Wei W and Shen X: Fractalkine/CX3CR1 induces apoptosis resistance
and proliferation through the activation of the AKT/NF-κB cascade
in pancreatic cancer cells. Cell Biochem Funct. 35:315–326. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Luo W, Lin Y, Meng S, Guo Y, Zhang J and
Zhang W: miRNA-296-3p modulates chemosensitivity of lung cancer
cells by targeting CX3CR1. Am J Transl Res. 8:1848–1856.
2016.PubMed/NCBI
|
|
28
|
Yao X, Qi L, Chen X, Du J, Zhang Z and Liu
S: Expression of CX3CR1 associates with cellular migration,
metastasis, and prognosis in human clear cell renal cell carcinoma.
Urol Oncol. 32:162–170. 2014. View Article : Google Scholar
|
|
29
|
Xu Z, Zheng X, Yang L, Liu F, Zhang E,
Duan W, Bai S, Safdar J, Li Z and Sun C: Chemokine receptor 7
promotes tumor migration and invasiveness via the RhoA/ROCK pathway
in metastatic squamous cell carcinoma of the head and neck. Oncol
Rep. 33:849–855. 2015. View Article : Google Scholar
|
|
30
|
Lv Z, Hu M, Ren X, Fan M, Zhen J, Chen L,
Lin J, Ding N, Wang Q and Wang R: Fyn mediates high glucose-induced
actin cytoskeleton reorganization of podocytes via promoting ROCK
activation in vitro. J Diabetes Res. 2016:56718032016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Hamaguchi M, Yamagata S, Thant AA, Xiao H,
Iwata H, Mazaki T and Hanafusa H: Augmentation of metalloproteinase
(gelatinase) activity secreted from Rous sarcoma virus-infected
cells correlates with transforming activity of src. Oncogene.
10:1037–1043. 1995.PubMed/NCBI
|
|
32
|
Hunter T: A tail of two src's: Mutatis
mutandis. Cell. 49:1–4. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Parsons JT, Martin KH, Slack JK, Taylor JM
and Weed SA: Focal adhesion kinase: A regulator of focal adhesion
dynamics and cell movement. Oncogene. 19:5606–5613. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Figel S and Gelman IH: Focal adhesion
kinase controls prostate cancer progression via intrinsic kinase
and scaffolding functions. Anticancer Agents Med Chem. 11:607–616.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Rentala S, Chintala R, Guda M, Chintala M,
Komarraju AL and Mangamoori LN: Atorvastatin inhibited
Rho-associated kinase 1 (ROCK1) and focal adhesion kinase (FAK)
mediated adhesion and differentiation of
CD133+CD44+ prostate cancer stem cells.
Biochem Biophys Res Commun. 441:586–592. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Schlaepfer DD, Hanks SK, Hunter T and van
der Geer P: Integrin-mediated signal transduction linked to Ras
pathway by GRB2 binding to focal adhesion kinase. Nature.
372:786–791. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Jin JK, Dayyani F and Gallick GE: Steps in
prostate cancer progression that lead to bone metastasis. Int J
Cancer. 128:2545–2561. 2011. View Article : Google Scholar : PubMed/NCBI
|
